132217Preclinical Proof of Concept for a Cell Therapy Delivery MatrixClosedFeasibility StudiesInnovate UKEmerging cell therapies have vast potential in the treatment of currently incurable diseases; the potential market for cell-based therapies being over 100 million patients in the US alone. Some of the main targets include heart disease, diabetes, neurodegenerative diseases, musculoskeletal disorders, spinal cord injury, stroke, autoimmune diseases and trauma. A current barrier to success is inefficienct clinical administration of these therapies to the patient. This is due to underdeveloped methods for presenting the cells that results in the majority of them dying or migrating away soon after injection. This project aims to redresss this issue by creating purpose-built delivery vehicles that provide protective environments and solidify upon injection; thus improving the survival, localisation, and clinical effectiveness of cell therapy. In this programme of work, we will demonstrate these concepts within clinically-relevant preclinical models. Finance Summary Table – How to complete this sectionmmary